MVK and neoplasm: 111In-DOTA-MVK(ε)-TATE exhibited a comparable level of tumor uptake (5.44 ± 0.19 %IA/g; p= 0.693) but showed a notable reduction in kidney retention compared to 111In-DOTA-TATE (5.56 ± 0.29 %IA/g; p < 0.001), resulting in an improved T/K ratio of 0.98.